Literature DB >> 23571539

Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.

Harsh Mathur1, Paula M O'Connor, Colin Hill, Paul D Cotter, R Paul Ross.   

Abstract

Due to the ongoing problem of recurrence of Clostridium difficile-associated diarrhea following antibiotic treatment, there is an urgent need for alternative treatment options. We assessed the MICs of five antimicrobials singly and in combinations against a range of C. difficile clinical isolates. Ramoplanin-actagardine combinations were particularly effective, with partial synergistic/additive effects observed against 61.5% of C. difficile strains tested.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23571539      PMCID: PMC3716125          DOI: 10.1128/AAC.00261-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial.

Authors:  P Patrick Basu; Amreen Dinani; Krishna Rayapudi; Tommy Pacana; Niraj James Shah; Hemant Hampole; N V Krishnaswamy; Vinod Mohan
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

Review 2.  The gut flora as a forgotten organ.

Authors:  Ann M O'Hara; Fergus Shanahan
Journal:  EMBO Rep       Date:  2006-07       Impact factor: 8.807

3.  Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital.

Authors:  Olle Aspevall; Annika Lundberg; Lars G Burman; Thomas Akerlund; Bo Svenungsson
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

4.  In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole.

Authors:  T Peláez; L Alcalá; R Alonso; A Martín-López; V García-Arias; M Marín; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 5.  Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence.

Authors:  Konstantinos Z Vardakas; Konstantinos A Polyzos; Konstantina Patouni; Petros I Rafailidis; George Samonis; Matthew E Falagas
Journal:  Int J Antimicrob Agents       Date:  2012-03-06       Impact factor: 5.283

6.  The fractional inhibitory concentration (FIC) index as a measure of synergy.

Authors:  M J Hall; R F Middleton; D Westmacott
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

7.  Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest.

Authors:  S S Wong; P C Woo; W K Luk; K Y Yuen
Journal:  Diagn Microbiol Infect Dis       Date:  1999-05       Impact factor: 2.803

8.  Clostridium difficile infection and treatment in the pediatric inflammatory bowel disease population.

Authors:  Ethan Mezoff; Elizabeth A Mann; Kim Ward Hart; Christopher J Lindsell; Mitchell B Cohen
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-04       Impact factor: 2.839

9.  Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study.

Authors:  Daniel M Musher; Nancy Logan; Adam M Bressler; David P Johnson; Jean-François Rossignol
Journal:  Clin Infect Dis       Date:  2009-02-15       Impact factor: 9.079

10.  Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.

Authors:  Wafa N Al-Nassir; Ajay K Sethi; Michelle M Nerandzic; Greg S Bobulsky; Robin L P Jump; Curtis J Donskey
Journal:  Clin Infect Dis       Date:  2008-07-01       Impact factor: 9.079

View more
  19 in total

Review 1.  The potential for emerging therapeutic options for Clostridium difficile infection.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2014

2.  Bacteriocins: Not Only Antibacterial Agents.

Authors:  Djamel Drider; Farida Bendali; Karim Naghmouchi; Michael L Chikindas
Journal:  Probiotics Antimicrob Proteins       Date:  2016-12       Impact factor: 4.609

3.  Characterization of the stereochemical configuration of lanthionines formed by the lanthipeptide synthetase GeoM.

Authors:  Neha Garg; Yuki Goto; Ting Chen; Wilfred A van der Donk
Journal:  Biopolymers       Date:  2016-11       Impact factor: 2.505

4.  Spirotetronate antibiotics with anti-Clostridium activity from Actinomadura sp. 2EPS.

Authors:  Jirayut Euanorasetr; Bungonsiri Intra; Phayungsak Mongkol; Surang Chankhamhaengdecha; Patoomratana Tuchinda; Mihoko Mori; Kazuro Shiomi; Takuya Nihira; Watanalai Panbangred
Journal:  World J Microbiol Biotechnol       Date:  2014-12-28       Impact factor: 3.312

5.  Conformational remodeling enhances activity of lanthipeptide zinc-metallopeptidases.

Authors:  Chang Zhao; Wangjian Sheng; Ying Wang; Jie Zheng; Xiangqian Xie; Yong Liang; Wanqing Wei; Rui Bao; Huan Wang
Journal:  Nat Chem Biol       Date:  2022-05-05       Impact factor: 16.174

Review 6.  Therapeutic Application of Lantibiotics and Other Lanthipeptides: Old and New Findings.

Authors:  Anton Du Preez van Staden; Winschau F van Zyl; Marla Trindade; Leon M T Dicks; Carine Smith
Journal:  Appl Environ Microbiol       Date:  2021-06-25       Impact factor: 4.792

7.  The SOS Response Master Regulator LexA Is Associated with Sporulation, Motility and Biofilm Formation in Clostridium difficile.

Authors:  Beata M Walter; Stephen T Cartman; Nigel P Minton; Matej Butala; Maja Rupnik
Journal:  PLoS One       Date:  2015-12-18       Impact factor: 3.240

Review 8.  Bacteriocin-Antimicrobial Synergy: A Medical and Food Perspective.

Authors:  Harsh Mathur; Des Field; Mary C Rea; Paul D Cotter; Colin Hill; R Paul Ross
Journal:  Front Microbiol       Date:  2017-06-29       Impact factor: 5.640

Review 9.  A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.

Authors:  Csaba Fehér; Alex Soriano; Josep Mensa
Journal:  Infect Dis Ther       Date:  2016-12-01

10.  The efficacy of thuricin CD, tigecycline, vancomycin, teicoplanin, rifampicin and nitazoxanide, independently and in paired combinations against Clostridium difficile biofilms and planktonic cells.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; Colin Hill; R Paul Ross
Journal:  Gut Pathog       Date:  2016-06-02       Impact factor: 4.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.